New Video: Novaliq Targeting Phenotypes in Dry Eye Disease Interview at OIS@ASCRS 2019
Christian Roesky, PhD, CEO of Novaliq was interviewed by Ehsan Sadri, MD, FACS, FAAO and discussed how to treat Dry Eye Disease in the future based on the pivotal clinical trial results of NOV03 and CyclASol
Novaliq named Finalist in “Clinical Trial Result of the Year” category of the LifeStars Awards 2019
Heidelberg, Germany – September 10, 2019 – Novaliq is pleased to announce that it has been recognised in the finalist roster of the Clinical Trial of the Year at the 2019 Lifestars AwardsTM.
New Video: Novaliq at OIS@ASCRS
Based on the new pivotal clinical trial results of NOV03 and CyclASol which were presented at the ASCRS, rethinking DED treatment becomes a reality.
New Video: Novaliq at ASCRS
Christian Roesky discusses how the company is rethinking DED therapy
Novaliq and BLP Management Group Established New Company, Betaliq Inc., to Leverage EyeSol Technology to Treat Glaucoma
- Betaliq is developing ophthalmic ß-blockers for the treatment of glaucoma using Novaliq’s waterfree EyeSol® technology
- Betaliq successfully collected proceeds in a Series A round
New OIS-podcast, Episode 215
Listen in to Bernhard Günther, founder of Novaliq, about the company’s trailblazing start and promising future
Novaliq named Finalist in “Clinical Trial Result of the Year” category of the Clinical & Research Excellence Awards CARE 2019
- Novaliq is recognized for its SEECASE clinical trial results of NOV03 demonstrating unprecedented sign and symptom improvements for Dry Eye Disease (DED) patients while offering an excellent safety profile
- NOV03 is potentially the first drug targeting the key underlying cause of evaporative DED, the leading reason for this undertreated disease that impacts visual function
New Video: Novaliq discussed at the Hawaiian Eye conference
Video: New water-free dry eye drop shows promising clinical results
New Video: Novaliq at Biotech Showcase
New Video: Novaliq making headway with its water-free eye drops. Have a look at the video:
Nicox Focuses Research Activities on Novel NO-Donating PDE5 Inhibitors for Glaucoma and Enters into Collaboration with Novaliq on Innovative Topical Ophthalmic Formulations
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it will be focusing its research activities on topical nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitors and soluble guanylate cyclase (sGC) stimulators. As part of this focus, Nicox has entered into a research collaboration with Novaliq GmbH for the development of novel topical ophthalmic formulations of Nicox’s NO-donating PDE5 inhibitors based on Novaliq’s water-free enabling EyeSol® technology, for lowering intraocular pressure (IOP).
Season’s Greetings!
Thank you for your commitment and support in 2018. We wish you and your family a terrific Holiday Season and a good start to a healthy and successful New Year. See you in 2019 ?
New Video: Novaliq at OIS
New Video: Novaliq presented positive topline data for two drugs in late-stage clinical trials. Have a look at the OIS video:
Novaliq announces positive topline results for its SEECASE phase 2 trial of NOV03 for the treatment of patients with dry eye disease
- The SEECASE trial met its prespecified primary endpoint for both treatment schedules at 8 weeks
- The trial further demonstrated pronounced improvements in a number of symptoms with statistical significance at all timepoints
- NOV03 is the first drug targeting evaporative dry eye disease associated with meibomian gland dysfunction
New Video: Novaliq at the Ophthalmology Futures Forums
Our CEO, Christian Roesky, illustrated at the Ophthalmology Futures Forums how Novaliq will take on the challenge to break the vicious circle of Dry Eye Disease.
Novaliq announces positive topline results for its CyclASol® phase 2b/3 ESSENCE trial in patients with Dry Eye Disease
- The ESSENCE trial met its primary endpoint at 4 weeks and demonstrated superiority of CyclASol® over vehicle in change from baseline on corneal fluorescein staining
- CyclASol® further showed statistically significant improvements over vehicle in secondary symptom endpoints
- CyclASol® demonstrated an early onset of action, exceptional tolerability profile due to the benefits of its water-free formulation and its unique mechanism of active drug delivery
Novaliq raises New Capital to accelerate the Commercialization of its Lead Products for Dry Eye Disease
Heidelberg, Germany – Oct 11, 2018 – Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology, today announces it has raised USD 53 million to further support its late-stage products and earlier pipeline programs.
In Australia, NovaTears® eye drops are available on the Pharmaceutical Benefits Scheme (PBS) from now on
- Using innovative new technology, NovaTears® effectively establishes a new class of treatment for Evaporative Dry Eye.
- Free from preservatives, water and phosphates, and can be used for up to six months after opening.
Novaliq to present at the Ophthalmology Futures Forum on how to break the vicious circle of Dry Eye Disease
Heidelberg, Germany – Sep 19, 2018 – Novaliq will present at the upcoming Ophthalmology Futures Forums in Vienna.
The Ophthalmology Futures Forums were established in 2012 to fill a void with regard to industry – investor meetings specifically for ophthalmology in Europe and Asia. The Forums focus on all aspects of global innovation in ophthalmology by connecting scientists, physicians, regulators, corporate leaders, venture capitalists and other investors who support the advancement of eye care.
Novaliq’s NovaTears® Treatment for Evaporive Dry Eye Disease is now available across Australia and New Zealand
Heidelberg, Germany – June 28, 2018 – Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, announced that NovaTears®, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD), is now also available in Australia.
Novaliq at Ophthalmology Technology Summit 2018
June 26, 2018 – We are delighted that Novaliq was selected as one of only four companies to present in OCTANe’s LaunchPad session during the Ophthalmology Technology Summit taking place in Newport Beach, CA on June 29, 2018. Novaliq Inc‘s president, Bernhard Günther, will present between 3:15-4:15 p.m. https://www.ots2018.com/agenda/